Yao Fu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Yao Fu has a total of 343 co-authors. Here are the top co-authors by number of shared publications:
- Gang Li
Department of General Surgery, The Affiliated Cancer Hospital of Nanjing Medical University & Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research
34 shared publications - Guangfu Jin
State Key Laboratory of Reproductive Medicine and Offspring Health, Nanjing Medical University, Nanjing, China
34 shared publications - Caiwang Yan
Department of Epidemiology, Center for Global Health, School of Public Health Nanjing Medical University Nanjing Jiangsu China
33 shared publications - Cheng Wang
Department of Epidemiology, Center for Global Health, School of Public Health, Nanjing Medical University, Nanjing, Jiangsu, China
33 shared publications - Fengyuan Li
Department of Epidemiology, State Key Laboratory Cultivation Base of Biomarkers for Cancer Precision Prevention and Treatment, Collaborative Innovation Center for Cancer Personalized Medicine, School of Public Health, Nanjing Medical University, Nanjing, China
33 shared publications - Hao Xu
Department of General Surgery The First Affiliated Hospital of Nanjing Medical University Nanjing China
33 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by Springer Nature in Research Square
Consistent Liver Function Support from Gene-Edited Pigs to Non-Human Primate Acute Liver Failure Models via Extracorporeal Liver Cross-Circulation
Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are severe, rapidly progressing conditions. Existing non-biological artificial liver support has limited efficacy, and liver transplantation is constrained by donor shortage and the time window. Extracorporeal liver cross-circulation (ELC) using gene-edited (GE) pigs offers a promising bridging therapy. Here, six Tibetan macaque ALF models were connected via ELC to 8GE pig livers under normothermic machine perfusion for 74–144 h to assess feasibility and functional support. Basic vital signs of the recipients, including heart rate, body temperature, and mean arterial pressure, remained relatively stable. Their AST/ALT rose then declined, total bilirubin trended upward, albumin and total protein remained stable, and bile secretion was continuous, indicating effective replacement of impaired liver function. INR and fibrinogen remained relatively stable, while platelets dropped sharply and stayed low, suggesting generally maintainable coagulation but thrombocytopenia. Complement, immunoglobulins, and B/T/NK cells remained low, indicating good immunosuppression. Donor liver injury was mainly ischemia/reperfusion- and inflammation-mediated, without typical hyperacute or acute rejection. In summary, 8GE pig livers under room-temperature ex vivo cross-perfusion maintained stable vital signs in ALF recipients, supported liver function for >72 h in all six recipients (up to 144 h), and effectively avoided hyperacute and acute rejection, providing a feasible strategy and key data for the safety and efficacy of clinical ELC.
- 2 November 2026
- Published by Springer Nature in Research Square
Open AccessConsistent Liver Function Support from Gene-Edited Pigs to Non-Human Primate Acute Liver Failure Models via Extracorporeal Liver Cross-Circulation
Acute liver failure (ALF) and acute-on-chronic liver failure (ACLF) are severe, rapidly progressing conditions. Existing non-biological artificial liver support has limited efficacy, and liver transplantation is constrained by donor shortage and the time window. Extracorporeal liver cross-circulation (ELC) using gene-edited (GE) pigs offers a promising bridging therapy. Here, six Tibetan macaque ALF models were connected via ELC to 8GE pig livers under normothermic machine perfusion for 74–144 h to assess feasibility and functional support. Basic vital signs of the recipients, including heart rate, body temperature, and mean arterial pressure, remained relatively stable. Their AST/ALT rose then declined, total bilirubin trended upward, albumin and total protein remained stable, and bile secretion was continuous, indicating effective replacement of impaired liver function. INR and fibrinogen remained relatively stable, while platelets dropped sharply and stayed low, suggesting generally maintainable coagulation but thrombocytopenia. Complement, immunoglobulins, and B/T/NK cells remained low, indicating good immunosuppression. Donor liver injury was mainly ischemia/reperfusion- and inflammation-mediated, without typical hyperacute or acute rejection. In summary, 8GE pig livers under room-temperature ex vivo cross-perfusion maintained stable vital signs in ALF recipients, supported liver function for >72 h in all six recipients (up to 144 h), and effectively avoided hyperacute and acute rejection, providing a feasible strategy and key data for the safety and efficacy of clinical ELC.
- 19 February 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 281, 156380
Molecular and histopathological insights into renal neuroendocrine tumors (RenNETs): A comprehensive study
- 19 February 2026
- Published by Elsevier in Pathology - Research and Practice
- Vol. 281, 156380
Molecular and histopathological insights into renal neuroendocrine tumors (RenNETs): A comprehensive study
- 5 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (4) , 813-830
PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma
Deubiquitinases (DUBs) are pivotal in cancer progression, yet their role in metabolic reprogramming in gastric adenocarcinoma (GAC) remains unclear. Here, we discover that highly expressed PSMD14 strengthens tumor stemness and drives tumor progression by increasing glycolysis and lactate accumulation, which activates H3K27 lactylation (H3K27la) and turns to enhance the expression of PSMD14 and SOX9. Mechanistically, PSMD14 deubiquitinates PFKFB2 at K355, facilitating SCYL2-mediated phosphorylation of PFKFB2 at S466/S483, which increases the generation of fructose-2,6-bisphosphate, activating PFK1 and glycolysis. Additionally, the H3K27la/PSMD14/SCYL2/p-PFKFB2 axis correlates with increased glucose metabolic activity and poor prognosis in GAC patients. Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC.
- 5 November 2025
- Published by Springer Nature in Cell Death & Differentiation
- Vol. 33 (4) , 813-830
PSMD14-mediated PFKFB2 deubiquitination activates H3K27 lactylation to drive cancer stemness in gastric adenocarcinoma
Deubiquitinases (DUBs) are pivotal in cancer progression, yet their role in metabolic reprogramming in gastric adenocarcinoma (GAC) remains unclear. Here, we discover that highly expressed PSMD14 strengthens tumor stemness and drives tumor progression by increasing glycolysis and lactate accumulation, which activates H3K27 lactylation (H3K27la) and turns to enhance the expression of PSMD14 and SOX9. Mechanistically, PSMD14 deubiquitinates PFKFB2 at K355, facilitating SCYL2-mediated phosphorylation of PFKFB2 at S466/S483, which increases the generation of fructose-2,6-bisphosphate, activating PFK1 and glycolysis. Additionally, the H3K27la/PSMD14/SCYL2/p-PFKFB2 axis correlates with increased glucose metabolic activity and poor prognosis in GAC patients. Notably, high-throughput screening of FDA-approved drugs reveals that Daclatasvir (DCV) exhibits high binding affinity for PSMD14 protein, disrupts the PSMD14-PFKFB2 interaction, reduces PFKFB2 activity and tumor burden. Collectively, our findings are the first to elucidate a positive feedback loop existing between PSMD14 and glycolysis in GAC progression, suggesting that PSMD14 blockade may represent a potential therapeutic approach for GAC.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S4 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of mutation burden between IGC and DGC across molecular subtypes reported in different studies.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S4 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of mutation burden between IGC and DGC across molecular subtypes reported in different studies.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S3 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of mutation burden between IGC and DGC according to different studies.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S3 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of mutation burden between IGC and DGC according to different studies.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S17 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of the proportion of samples with biallelic inactivation in TP53 across IGC and DGC.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S17 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of the proportion of samples with biallelic inactivation in TP53 across IGC and DGC.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S10 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Analysis of focal amplification differences and their transcriptional impact in IGC and DGC.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S10 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Analysis of focal amplification differences and their transcriptional impact in IGC and DGC.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S5 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of mutation burden according to alcohol drinking, smoking, and H. pylori infection status.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S5 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Comparison of mutation burden according to alcohol drinking, smoking, and H. pylori infection status.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Fig. S22 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Schematics of protein changes in BMP6, CFTR, and MTRR identified in IM and GC.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Fig. S22 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Schematics of protein changes in BMP6, CFTR, and MTRR identified in IM and GC.
- Open Access
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Table S2 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Analysis of mutation burden across molecular subtypes with adjustments for age.
- 15 August 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S2 from Genomic Analyses Reveal the Evolving Characteristics of Intestinal Metaplasia and Gastric Cancer
Analysis of mutation burden across molecular subtypes with adjustments for age.